Strongbridge Biopharma plc (NASDAQ:SBBP) Expected to Post Earnings of -$0.28 Per Share

Brokerages forecast that Strongbridge Biopharma plc (NASDAQ:SBBP) will post ($0.28) earnings per share for the current quarter, according to Zacks. Five analysts have made estimates for Strongbridge Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.25). Strongbridge Biopharma reported earnings of ($0.47) per share in the same quarter last year, which would indicate a positive year over year growth rate of 40.4%. The company is expected to issue its next earnings results on Wednesday, October 30th.

According to Zacks, analysts expect that Strongbridge Biopharma will report full-year earnings of ($1.01) per share for the current year, with EPS estimates ranging from ($1.04) to ($0.98). For the next financial year, analysts expect that the firm will post earnings of ($0.86) per share, with EPS estimates ranging from ($1.00) to ($0.62). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.01. The company had revenue of $6.08 million during the quarter, compared to analyst estimates of $4.82 million. Strongbridge Biopharma had a net margin of 181.52% and a return on equity of 49.92%.



Several research firms have commented on SBBP. HC Wainwright reaffirmed a “buy” rating on shares of Strongbridge Biopharma in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. ValuEngine raised shares of Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Evercore ISI began coverage on shares of Strongbridge Biopharma in a report on Tuesday, September 24th. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group began coverage on shares of Strongbridge Biopharma in a report on Tuesday, September 24th. They set a “buy” rating and a $8.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $9.90.

Several institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Strongbridge Biopharma in the second quarter worth about $42,000. Sphera Funds Management LTD. lifted its holdings in shares of Strongbridge Biopharma by 2.1% in the first quarter. Sphera Funds Management LTD. now owns 951,600 shares of the biotechnology company’s stock worth $4,739,000 after buying an additional 20,000 shares in the last quarter. Alambic Investment Management L.P. purchased a new stake in shares of Strongbridge Biopharma in the second quarter worth about $66,000. Northern Trust Corp purchased a new stake in shares of Strongbridge Biopharma in the second quarter worth about $96,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in shares of Strongbridge Biopharma in the second quarter worth about $112,000. 52.25% of the stock is currently owned by hedge funds and other institutional investors.

SBBP traded down $0.06 during trading on Friday, hitting $2.01. 141,611 shares of the company traded hands, compared to its average volume of 231,540. The firm has a market cap of $116.50 million, a P/E ratio of 6.48 and a beta of 0.81. Strongbridge Biopharma has a one year low of $2.02 and a one year high of $6.52. The stock’s fifty day moving average is $2.54 and its 200 day moving average is $3.21.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

Further Reading: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.